Elanco Animal Health Incorporated $ELAN Shares Sold by Northern Trust Corp

Key Points

• Northern Trust Corp reduced its stake in Elanco Animal Health by 1.0%, selling 27,996 shares and holding approximately 2.9 million shares worth about $30.6 million by the end of the first quarter.
• Despite Northern Trust's reduction, several other institutional investors have increased their holdings significantly, with Allworth Financial LP boosting its stake by 791.7% during the same period.
• Elanco reported better-than-expected quarterly earnings, with $0.26 earnings per share (EPS), surpassing analyst expectations of $0.20, and projected future EPS guidance between 0.850-0.91 for FY 2025.

Northern Trust Corp cut its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 1.0% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,915,690 shares of the company's stock after selling 27,996 shares during the period. Northern Trust Corp owned about 0.59% of Elanco Animal Health worth $30,615,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ELAN. First Trust Advisors LP grew its position in Elanco Animal Health by 508.2% in the fourth quarter. First Trust Advisors LP now owns 133,038 shares of the company's stock worth $1,611,000 after acquiring an additional 111,163 shares in the last quarter. Stifel Financial Corp lifted its stake in Elanco Animal Health by 103.6% in the fourth quarter. Stifel Financial Corp now owns 228,277 shares of the company's stock worth $2,764,000 after purchasing an additional 116,175 shares during the last quarter. Aquatic Capital Management LLC bought a new stake in Elanco Animal Health in the fourth quarter worth $232,000. Comerica Bank lifted its stake in Elanco Animal Health by 357.9% in the fourth quarter. Comerica Bank now owns 33,926 shares of the company's stock worth $411,000 after purchasing an additional 26,517 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV bought a new stake in Elanco Animal Health in the fourth quarter worth $803,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Price Performance

Shares of ELAN stock traded down $0.04 on Thursday, hitting $17.32. 2,212,786 shares of the stock traded hands, compared to its average volume of 5,994,885. The firm has a market cap of $8.60 billion, a price-to-earnings ratio of 20.09, a PEG ratio of 3.41 and a beta of 1.62. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $18.87. The firm has a 50 day simple moving average of $15.81 and a two-hundred day simple moving average of $12.83. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The firm had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same period in the previous year, the firm posted $0.30 EPS. The business's quarterly revenue was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. As a group, equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ELAN. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. UBS Group upped their price objective on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Zacks Research cut shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 20th. Piper Sandler increased their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a research note on Monday, August 11th. Finally, Leerink Partners raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 price target for the company in a research note on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Elanco Animal Health currently has an average rating of "Moderate Buy" and a consensus target price of $17.33.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.